Genmab — Juni 2019

[gentogen]

Ansøgning var d. 12/3

[gentogen]

Kadcyla var "just over 12 weeks", så det svarer vel stort set til i dag

[peter12]

AQR har så til gengæld reduceret shorts med ca 0,1% til 1.79 %

[peter12]

De har nok fået besked på at levere dem tilbage igen

[bikube]

Jeg er da imponeret over, at en statslig institution sender den slags opdateringer på en helligdag. God service.
Jeg følger da med i, hvor meget mine aktier er shortet, men jeg tager det som en extra mulighed for stigning, da shorts jo skal lukkes engang.

[peter12]

De skal selv indberette, så mon ikke det sker automatisk ?

[bikube]

Sikkert.

[transalp]

Go morgen..

[polle1]

God morgen og god dag

[Tandfeen-2]

Ny tech aftale med Janssen

[Tandfeen-2]

https://ir.genmab.com/news-releases/news-release-details/genmab-signs-agreement-janssen-next-generation-cd38-antibody

[Helge_LarsenPI-redaktør]

God morgen.

[Helge_LarsenPI-redaktør]

Tusinde tak Tandfe.

[E_L]

it seems they want to build the Dara successor / patent extension? Janssen logical partner, also as they can probably not work on on any CD38 myeloma targets themselves under the current contract

[Sukkeralf]

Probably both life cycle management and maybe a stronger solid tumor candidate - but nice to see a commerciel HexaBody deal. Great

[Solsen]

We have seen hexabody tech. add potency. Very good to se JNJ want to grab the chance to be on board with hexa.

[Helge_LarsenPI-redaktør]

Better late than never.

[Legolas23]

Bert good news !

[Legolas23]

Very

[E_L]

am I reading it correctly that ALL development costs will be for Genmab, until Janssen exercises its option?